APA (7th ed.) Citation

Huo, G., Liu, W., & Chen, P. (2024). Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer. Journal of Gynecologic Oncology, 35(5), 1. https://doi.org/10.3802/jgo.2024.35.e58

Chicago Style (17th ed.) Citation

Huo, Gengwei, Wenjie Liu, and Peng Chen. "Cost-effectiveness of Tisotumab Vedotin as a Second- or Third-line Therapy for Cervical Cancer." Journal of Gynecologic Oncology 35, no. 5 (2024): 1. https://doi.org/10.3802/jgo.2024.35.e58.

MLA (9th ed.) Citation

Huo, Gengwei, et al. "Cost-effectiveness of Tisotumab Vedotin as a Second- or Third-line Therapy for Cervical Cancer." Journal of Gynecologic Oncology, vol. 35, no. 5, 2024, p. 1, https://doi.org/10.3802/jgo.2024.35.e58.